Tolerance in Beekeepers

November 24, 2023 updated by: University Hospital Plymouth NHS Trust

Elucidation of the Mechanism of Immune Tolerance in Beekeepers

Beekeepers experience multiple bee stings each year. Many of these beekeepers (25-60%) become sensitized to bee venom through the production of specific antibodies that target the bee venom. Although these antibodies are important in the triggering of an allergic reaction only a small number of sensitised beekeepers go on to have an allergic reaction with symptoms away from the site of the sting. These reactions can be severe and are known as anaphylactic reactions.

The study investigates why some beekeepers develop severe allergic symptoms after bee stings while others do not.

This study will explore factors in the blood that protect sensitised individuals from having anaphylactic reactions - meaning that despite being sensitised they are tolerant and do not react to subsequent stings.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Beekeepers experience multiple stings each year many of whom (25-60%) become sensitised to bee (apis mellifera) venom through the production of IgE antibodies (1,2). However only a small proportion of the sensitised group go on to have anaphylaxis to bee venom. This study will investigate differences in T cell tolerance to bee venom in 3 groups by exploring factors that "protect" sensitised individuals from having anaphylactic reactions - meaning that despite being sensitised they are tolerant and do not react to subsequent stings.

T regulatory cell (Tregs) play a critical role in promoting immune tolerance to allergens and Treg generation has been shown to occur in bee venom allergic individuals following venom desensitisation therapy (3.4). Observations in sensitised tolerant (non-allergic) beekeepers (TB) suggest that exposure to venom through bee stings results in a similar increase in the frequencies of induced Tregs (iTregs) (5). Helios negative induced Treg cells have also been suggested to contribute significantly to the establishment of immune tolerance in beekeepers. We will analyse the differences in Treg and Teffector (Teff) populations comparing sensitised beekeepers who are able to tolerate venom exposure (sensitised, tolerant beekeepers TB) with those beekeepers who do develop symptoms of systemic allergic reactions following bee sting (AB). A group of non-sensitised (NS) individuals will be recruited as a control population. We will perform RNA-seq to analyse the gene expression in Treg cells and Teff cells from all three groups. This will help to identify molecular targets that are involved in inducing the allergic reaction and also the genes that are involved in suppressing this reaction.

Considering the outcome of tolerance or anaphylaxis following bee stings, and the role of Treg and Teff cells in these processes, we will investigate the epigenetic regulations involved, which determine these cell's function. RNA-seq analysis will provide critical information about the genes involved in allergic reaction or in its suppression. DNA and histone modification analyses in the regulatory regions of these genes will help to better understand the underlying mechanism.

This project will investigate why some beekeepers who are sensitised to bee venom are able to tolerate bee stings, while in other sensitised individuals a bee sting can lead to life threatening anaphylaxis. This is not only of significance to beekeepers, but also has potential implications for the understanding of allergen tolerance in other allergic disease.

Study Type

Observational

Enrollment (Estimated)

120

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Group 1 inclusion criteria. Individuals naive to beekeeping (<2 previous bee stings, none in the last 24 months).

No history of anaphylaxis to bee stings.

Group 2 inclusion criteria. Beekeepers with > approximately 10 stings/year who have been beekeeping for >3 years.

No history of anaphylaxis to bee stings.

Group 3 inclusion criteria Beekeepers with diagnosis of anaphylaxis to bee venom in the last 12 months who are sensitised to bee venom (as evidenced by positive specific IgE and positive skin test to bee venom).

Description

Inclusion Criteria:

- Group 1 inclusion criteria.

  • Individuals naive to beekeeping (<2 previous bee stings, none in the last 24 months)
  • no history of anaphylaxis to stings. Group 2 inclusion criteria.
  • Beekeepers with > approximately 10 stings/year who have been beekeeping for >3 years.
  • No history of anaphylaxis to bee venom. Group 3 inclusion criteria
  • Beekeepers with diagnosis of anaphylaxis to bee venom in the last 12 months who are sensitised to bee venom (as evidenced by positive specific IgE and positive skin test to bee venom)

Exclusion Criteria:

  • Unable to understand protocol/consent.
  • Unable to commit to follow up visits.
  • Participants with a known history of mastocytosis or under investigation for suspected mastocytosis.
  • Participants undergoing desensitisation treatment to bee venom before the first visit.
  • Participants being treatment with immunosuppressive medications. being treatment with immunosuppressive medications.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group 1
Individuals naïve to beekeeping (<2 previous bee stings, non in the last 24 months). No history of anaphylaxis
Skin prick test for bee venom
IgE/G and T cell tolerance studies
Group 2
Beekeepers with > approximately 10 stings/year who have been beekeeping for >3 years. No history of anaphylaxis.
Skin prick test for bee venom
IgE/G and T cell tolerance studies
Group 3
Beekeepers with diagnosis of anaphylaxis to bee venom in the last 12 months who are sensitised to bee venom ( as evidenced by positive IgE and positive skin test to bee venom)
Skin prick test for bee venom
IgE/G and T cell tolerance studies

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cell types
Time Frame: 3 years
Number and function of various cell types will be measured for each participant
3 years
Molecular and epigenetic profiles
Time Frame: 3 years
Molecular and epigenetic profiles will be measured in each participant
3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sensitisation data
Time Frame: 3 years
results of sensitisation data from the beginning and end of the beekeeping season will be compared
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2023

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

October 1, 2027

Study Registration Dates

First Submitted

November 24, 2023

First Submitted That Met QC Criteria

November 24, 2023

First Posted (Actual)

December 5, 2023

Study Record Updates

Last Update Posted (Actual)

December 5, 2023

Last Update Submitted That Met QC Criteria

November 24, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 330722

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bee Sting

Clinical Trials on skin prick test

3
Subscribe